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osting by EAbstract Doxilamine orodispersible tablets were developed with considerable increase in drug
release as compared to marketed formulations, seven formulations were developed and studied.
The difference in drug release values was found to be 100.45 ± 1.89 and 56.47 ± 1.89, respectively.
To prevent bitter taste and unacceptable odour of the drug, the drug was taste masked with weak
cation exchange resins like Indion 234, Indion 204 and Indion 414. The drug was characterized
according to different compendial methods, on the basis of identiﬁcation by UV spectroscopy,
pH, organoleptic properties and other tests. Among the three resins, one was selected for further
studies i.e., Indion 234, because of high drug loading capacity. Drug–resin complex was prepared
using batch method and effect of various processing parameters viz. drug–resin ratio, pH, temper-
ature and drug concentration was studied to optimize the loading conditions. Maximum loading
was obtained at drug–resin ratio 1:2, pH 5, temperature 50 C and drug concentration 4 mg/ml.
A successful taste masking of resinate was conﬁrmed by time intensity method and also by taking
drug release in 0.01 N hydrochloric acid and in simulated salivary ﬂuid. The values of pre-compres-
sion parameters evaluated, were within prescribed limits and indicated good free ﬂowing properties.
The data obtained of post-compression parameters such as weight variation, hardness, friability,
wetting time, water absorption ratio, content uniformity, disintegration time and dissolution and
was found superior over conventional formulation. The F5 batch with disintegration time
25.24 ± 0.75 and dissolution 100.46%± 3.78 was selected as optimized formulation. This was
compared with conventional marketed formulation and was found superior. Batch F5 was also sub-
jected to stability studies for three months and was tested for its disintegration time, drug contents96482585.
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230 T.Y. Puttewar et al.and dissolution behaviour monthly. It was observed that the contents of the tablets remained the
same. By an appropriate selection and combination of excipients it was possible to obtain orodis-
persible and taste masked tablets.
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The term ‘Orodispersible Tablet’ as appears in European Phar-
macopoeia (Suppl. 4.1, IV Ed.) is deﬁned as ‘‘uncovered tablet
for buccal cavity, where it disperses before ingestion’’. They
obviate the problem associated with conventional dosage
forms, it has beneﬁts like desired hardness, dosage uniformity,
extremely easy administration and since no water is required
for swallowing these tablets are suitable for geriatric, paediat-
ric and travelling patients. These tablets display a fast and
spontaneous de-aggregation in the mouth, soon after it comes
in contact with saliva, dissolving the active ingredient and
allowing absorption through all possible membrane it comes
in contact during deglutition (Sharma et al., 2008).
In the recent past, several new advanced technologies have
been introduced for the formulation of orodispersible tablets
with very interesting features, like extremely low disintegration
time, exceptional taste masking ability, pleasant mouth feel
and sugar free tablets for diabetic patients (Shukla et al.,
2009). The technologies utilized for fabrication of orodispers-
ible tablets include lyophilization (Virely and Yarwood,
1990), moulding (Pebley et al., 1994), direct compression
(Watanabe, 1995), cotton candy process (Myers et al., 1995),
spray drying (Allen and Wang, 1996), sublimation (Koizumi
et al., 1997), mass extrusion (Bhaskaran and Narmada,
2002), nanonization (Khan et al., 2007) and quick dissolve ﬁlm
formation (Khan et al., 2007). These techniques are based on
the principles of increasing porosity and/or addition of super-
disintegrants and water soluble excipients in the tablets
(Biradar et al., 2006). The formulations prepared from these
techniques differ from each other on the basis of the factors
like mechanical strength of ﬁnal product, drug and dosage
form stability, mouth feel, taste, rate of dissolution of the for-
mulation in saliva, rate of absorption from saliva and overall
drug bioavailability and polymers (Kuchekar et al., 2003).
Taste masking of the drug employing ion exchange resins
(IER) has proved to be safe and effective method for formula-
tion of various dosage forms.
In this paper we report the formulation and evaluation of
orodispersible tablet of taste masked doxylamine succinate.
Doxylamine succinate is an antihistaminic commonly used
to prevent morning sickness in pregnant women. It is an ex-
tremely bitter drug therefore it is very essential to mask the
bitter taste. It’s formulation into simple tablet may induce
vomiting, but formulation of taste masked doxylamine succi-
nate in orodispersible tablet will give rapid action and will
prevent morning sickness. Taste masking by ion exchange re-
sin i.e., Indion 234 was employed because of its better drug
loading and taste masking. Ion exchange resins have been
increasingly used for the taste masking of bitter taste drug
and help to prepare orodispersible tablets (Nandgude et al.,
2007).
Ion exchange resins are solid and suitable in solubilised
high molecular weight polyelectrolytes that can exchange theirmobile ions of equal charge with the surrounding medium
reversibly and stotiometrically. They are available in desired
size ranges. Bitter cationic drugs can get adsorbed on to the
weak cationic exchange resins of carboxylic acid functionally
to form the complex which is not bitter. Further resinates
can be formulated as lozenges, chewing gum, suspension or
dispersible tablet and mask the taste (Rishi, 2004). Drug can
be bound to the resin with the drug solution. Drugs are at-
tached to the oppositely charged resin substrate or resonate
through weak ionic bonding so that dissociation of the drug–
resin complex does not occur under salivary pH conditions.
This suitably masks the unpleasant taste and odour of drugs
(Kaushik et al., 2004).
Taste is an important parameter in administering drugs
orally. Undesirable taste is one of the important formulation
problems that are encountered with many drugs. Adminis-
tration of bitter drugs orally with acceptable level of palat-
ability is a key issue for health providers. Proven methods
for bitterness reduction and inhibition have resulted in im-
proved palatability of oral pharmaceuticals (jeong et al.,
2005). Taste masking is an essential requirement for fast dis-
solving tablets for commercial success. Taste masking of the
active ingredient can be achieved by various techniques.
Drugs with unacceptable bitter taste can be microencapsulat-
ed, such as Cefuroxime axetil can be microencapsulated in
various types of acrylic polymers, Beclamide can be coacer-
vated using gelatin. Macrolide antibiotics are having unac-
ceptable taste (erythromycin and clarithromycin; Yajima
et al., 1999) has reported successful taste masking using
monoglycrides.
2. Materials and methods
2.1. Materials
All materials used in the present research were commercial
samples. Active agent: Doxylamine succinate (Adroit Pharma-
ceuticals Pvt. Ltd., India), Pyridoxine HCL (Adroit Pharma-
ceuticals Pvt. Ltd., India); ION Exchange Resins: Indion 204,
Indion 234 and Indion 414 (ION Exchange India Ltd., Mum-
bai, India); Excipients: VIVAPUR 102 (Microcrystalline Cellu-
lose NF, Ph. Eur., JP), VIVASOL (Croscarmellose Sodium
Ph. Eur., NF. JPE), VIVASTAR P (Sodium Starch Glyco-
late, Ph. Eur.), Avicel PH 113 (Microcrystalline Cellulose
USP/NF, EP,JP), Kollidon CL-SF (Super Fine Grade Crossp-
ovidone USP/NF, EP, JPE), Lactopress Anhydrous 250 (b-
Lactose anhydrous USP/NF, EP, JP) and Ac–Di–Sol (Cro-
scarmellose Sodium, NF, Ph, Eur., JPE) were gift by JRS
PHARMA GmBH & CO. KG 73494, Rosenberg, Germany.
2.2. Preparation of tablets
The preparation of tablets was carried out after the analysis of
drug samples, ion exchange resins, mixture formation and their
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Figure 1 Effect of drug–resin ratio.
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Tablets (Rohm and Co, 2008).
2.2.1. Analysis of doxylamine succinate
The Doxylamine succinate was characterized according to dif-
ferent compendial methods and was found to be a white to crea-
mywhite crystalline powderwith characteristic odour. Found to
have a melting point in range of 103–106 C and a pH of 5, kmax
of 262 nm, all the ﬁndings matched the ofﬁcial reports.
2.2.1.1. Scanning of doxylamine succinate in 0.1 N hydrochloric
acid. The solution containing 20 lg/ml of doxylamine succi-
nate in 0.1 N hydrochloric acid was prepared and scanned over
range of 200–400 nm against 0.1 N hydrochloric acid as a
blank using Thermo Alfa Helios double beam UV spectropho-
tometer. The kmax was found to be 262.0 nm, which conﬁrms
to the reported value.
2.2.1.2. Preparation of dissolution medium for standard curves.
In the present work, doxylamine succinate was estimated by
UV spectrophotometry in distilled water, 0.01 N hydrochlo-
ric acid, 0.1 N hydrochloric acid and in simulated salivary
ﬂuid.
2.2.1.3. Preparation of standard calibration curve in distilled
water. Various drug concentrations (5–50 lg/ml) in distilled
water were prepared and the absorbance was measured at
262 nm.
For the standard curve, 100 mg of doxylamine succinate
was accurately weighed and dissolved in 100 ml of distilled
water, then 5 ml of the resulting solution was diluted to
100 ml with distilled water to make stock solution of concen-
tration 50 lg/ml. Further serial dilutions were carried out with
distilled water to get drug concentrations 5, 10, 15, 20, 25, 30,
35, 40, 45 and 50 lg/ml. The absorbance of dilutions was mea-
sured against distilled water as a blank at 262 nm using double
beam UV/Visible spectrophotometer. The plot of absorbance
Vs concentration was plotted and subjected to linear regression
analysis. Drug was found to obey Beer Lambert’s law in the
concentration range of 5–50 lg/ml.
2.2.1.4. Preparation of standard calibration curve in simulated
salivary ﬂuid. Various drug concentrations (5–50 lg/ml) in
simulated salivary ﬂuid were prepared and the absorbance
was measured at 262 nm (Clarke, 1986). For the standard
curve, 100 mg doxylamine succinate was accurately weighed
and dissolved in 100 ml of simulated salivary ﬂuid, and then
5 ml of the resulting solution was diluted to 100 ml with sim-
ulated salivary ﬂuid. Further serial dilutions were carried out
with simulated salivary ﬂuid to get drug concentrations 5, 10,
15, 20, 25, 30, 35, 40, 45 and 50 lg/ml. The absorbance of
dilutions was measured against simulated salivary ﬂuid as a
blank at 262 nm using double beam UV/visible spectropho-
tometer. The plot of absorbance Vs concentration was plot-
ted and subjected to linear regression analysis. Drug was
found to obey Beer Lambert’s law in the concentration range
of 5–50 lg/ml.
2.2.2. Analysis of ion exchange resin (IER)
The IER is selected on the basis of drug nature and require-
ments of the formulation. The study was carried out amongthree different resins viz. Indion 204, Indion 234 and Indion
414 in order to screen most suitable resin for complexation
with doxylamine succinate. Resinates were prepared using
batch method. In each case, 100 mg doxylamine succinate
in deionised water was stirred with 100 mg of resin using
magnetic stirrer at 500 rpm. The amount of drug loaded at
the end of 45 min was determined indirectly by estimating
the amount remaining to be loaded in solution spectrophoto-
metrically at 262 nm (United States Pharmacopoeia 28,
2005).
2.2.2.1. Effect of drug: resin ratio. The Indion 234 which
showed highest amount of drug loading for ratio 1:1 was opti-
mized for various drug:resin ratios. In each case, 100 mg of
doxylamine succinate was stirred with varying amount of resin
in deionised water using magnetic stirrer at 500 rpm. The
amount of drug loaded at different time intervals was deter-
mined indirectly by estimating the amount remaining to be
loaded in solution spectrophotometrically at 262 nm. A plot
of mean of three determinations for percentage drug loaded
as a function of time is plotted in Fig. 1. Results are displayed
in Table 1.
2.2.2.2. Effect of pH on drug loading. The study was carried out
at ﬁve pH values 3, 4, 5, 6 and 7. The pH was adjusted to de-
sired value using 2 N citric acid. Solution of 100 mg doxyla-
mine succinate drug was stirred with 200 mg of resin using
magnetic stirrer at 500 rpm. The amount of drug loaded at dif-
ferent time intervals was determined indirectly by estimating
the amount remaining to be loaded in solution spectrophoto-
metrically at 262 nm. A plot of mean of three determinations
for percentage drug loaded as a function of time at different
pH was obtained.
2.2.2.3. Effect of temperature on drug loading. The study was
carried out at four temperature conditions 30 C, 40 C,
50 C and 60 C. In each case, 100 mg of doxylamine succi-
nate was stirred with 200 mg of resin in deionised water using
magnetic stirrer at 500 rpm. The amount of drug loaded at
different time intervals was determined indirectly by estimat-
ing the amount remaining to be loaded in solution spectro-
photometrically at 262 nm. A plot of mean of three
determinations for percentage drug loaded as a function of
time was obtained.
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Figure 2 Drug release from DRC.
Table 1 Effect of drug–resin ratio.
Time
(min)
Percentage of drug loaded
A B C D
00 00 00 00 00
10 27.46 ± 0.26 42.61 ± 0.46 61.17 ± 0.53 64.58 ± 0.26
20 39.2 ± 0.46 55.86 ± 0.70 76.7 ± 0.93 78.97 ± 0.46
30 43.17 ± 1.85 61.35 ± 1.39 88.63 ± 1.39 85.6 ± 0.71
40 45.45 ± 1.38 78.40 ± 2.32 88.06 ± 2.78 84.08 ± 4.64
50 44.88 ± 0.92 78.97 ± 2.78 89.77 ± 1.85 84.65 ± 0.92
60 44.31 ± 2.31 78.97 ± 3.24 89.2 ± 0.46 84.09 ± 5.10
Results are the mean of three determinations.
Table 2 Drug release from DRC.
Sr. No. Time (min) Percentage drug release
1 0 0
2 2 31.77 ± 6.63
3 4 74.99 ± 7.55
4 6 87.33 ± 5.77
5 8 96.6 ± 3.93
6 10 97.37 ± 2.88
7 12 97.37 ± 2.18
8 15 97.37 ± 2.88
Results are mean of three determinations.
Table 3 Taste panel evaluation.
Batch Taste-masked Taste panel
A Yes Not acceptable worst than B
B Yes Not acceptable better than A
C Yes Maximum acceptability
D Yes Maximum acceptability
232 T.Y. Puttewar et al.2.2.2.4. Effect of drug concentration on drug loading. The study
was carried out at three different concentrations 2 mg/ml,
4 mg/ml and 6 mg/ml. In each case, solution equivalent to
100 mg drug was stirred with 200 mg resin in deionised water
using magnetic stirrer at 500 rpm. The amount of drug loaded
at different time intervals was determined indirectly by esti-
mating the amount remaining to be loaded in solution spectro-
photometrically at 262 nm. A plot of mean of three
determinations for percentage drug loaded as a function of
time was obtained.
2.2.2.5. Optimized conditions. Following are the optimum con-
ditions for the preparation of drug–resin complex of doxyla-
mine succinate and are best suited for optimum loading
(1) Drug:resin ratio: 1:2
(2) pH: pH 5
(3) Drug concentration: 4 mg/ml
(4) Time: 30 min
2.2.2.6. Preparation of drug–resin complex. In batch process,
200 mg of activated resin was placed in a beaker containing
deionised water and allow to swell for 30 min. Accurately
weighed doxylamine succinate 100 mg was added and stirred
for one hour. The mixtures were ﬁltered and residue was
washed with deionised water. DRC was then washed with suf-
ﬁcient quantity of deionised water for three times to remove
loosely adsorbed drug from resinate surface. DRC was allowed
to dry at room temperature and was stored in tightly closed
container and used in further studies.
2.2.3. Studies on drug – complexes
2.2.3.1. Drug release from DRC. Drug release from DRC was
determined using United States Pharmacopoeia (USP) type II
dissolution apparatus. DRC equivalent to 30 mg of resinate
was weighed accurately and added to 900 ml of 0.01 N hydro-
chloric acid and maintained at 37 C. Drug release was per-
formed at 50 rpm for 15 min. Aliquots of the medium were
withdrawn at regular intervals, ﬁltered and the absorbance
determined on spectrophotometer. From absorbance values,
percent drug dissolved at various time intervals was deter-
mined. A plot of mean of three determinations for percentage
drug released as a function of time is plotted in Fig. 2 and
results are displayed in Table 2.
2.2.3.2. Taste panel evaluation of different batches of resinate.
In this the different batches of resinate were tested to deter-mine most suitable ratio of complex for successful taste
masking.
The results (Table 3) showed excellent correlation with the
evaluation of the taste panel employed. From above observa-
tions, Formulation C was selected for further study.
2.2.3.3. Taste panel evaluation for ‘Batch C’ resinate. Bitterness
was quantitated by consensus of trained taste panel. A time
intensity method was used, in which a sample equivalent to a
normal dose was held in the mouth for 10 s (Fu et al., 1991).
Bitterness level were recorded immediately, then spat out
(Table 4).
A numerical scale was used with the following values: 0-
tasteless, 0.5-very slight, 1-slight, 1.5-slight to moderate, 2-
moderate, 2.5-moderate to strong, 3-strong, 3+-very strong.
2.2.3.4. ‘In vivo’ evaluation of drug complex. The said resinate
was given to panel of healthy human volunteers for taste mask-
ing evaluation using time intensity method which shows satis-
factory masking of taste (Table 5).
Table 4 Taste panel evaluation for ‘Batch C’ resinate.
Sr. No. Volunteers 10 s 1 min 2 min 5 min 10 min 15 min
1 1 0.7 ± 0.67 0.5 ± 0.31 0.2 ± 0.24 0.4 ± 0.58 0.2 ± 0.24 0
2 2 0.9 ± 0.58 0.3 ± 0.4 0 0.4 ± 0.58 0 0
3 3 0.6 ± 0.37 0.5 ± 0.44 0 0 0 0
4 4 0 0.3 ± 0.4 0 0 0 0
5 5 0 0.6 ± 0.37 0 0 0 0
6 6 0 0 0 0 0 0
7 7 0.4 ± 0.37 0 0 0.1 ± 0.2 0 0
8 8 0 0 0 0 0 0
9 9 0 0 0 0 0 0
10 10 0 0 0 0 0 0
Results are mean of ﬁve determinations.
Table 5 In vivo evaluation of drug complex.
Form of doxylamine succinate Degree of bitterness
Time 10 s 1 min 2 min 5 min 10 min 15 min
Pure drug 2.2 ± 0.63 2.8 ± 0.24 2.5 ± 0.54 1.7 ± 0.97 1.1 ± 0.58 0.7 ± 0.50
Drug–resin complex (c) 1.1 ± 0.73 0.7 ± 0.67 0 0 0 0
Results are mean of ﬁve determinations.
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the DRC was also performed in 10 ml of pH 6.7 solution by
adding drug complex equivalent to 10 mg of Doxylamine suc-
cinate to a test tube. The mixtures were ﬁltered after shaking
for 60 s. The ﬁltrates were assayed for drug. Drug resinates
are insoluble hence, even resinate of bitter drugs have virtually
no taste. With the correct selection of ion exchange resin, the
drug is not released in the mouth so that the patient does
not taste the drug when it is swallowed. The percentage drug
dissolved was found to be 1.96%± 0.50 at a drug–resin com-
plex ratio of 1:2.
2.2.3.6. X.R.P.D studies. The experiments were conducted on
pure drug, pure resin, physical mixture of drug and resin and
drug–resin complex for X-ray powder diffraction. The X-ray
diffractograms were prepared by using Philips X’Pert PROP
analytical XRD machine model PW1780.
The drug sample received from Adroit Pharmaceuticals
complies with the compendial speciﬁcations for identiﬁcation
and other tests, and is suitable for present studies. Previously
reported spectrophotometric methods of analysis of doxyla-
mine succinate was found suitable for the present work and
obeys Beer–Lambert’s law in working range in all the media
i.e., Distilled water, 0.01 N hydrochloric acid, 0.1 N hydro-
chloric acid and simulated salivary ﬂuid.
The ﬁrst step for puriﬁcation of resin was done by washing
with absolute ethanol, ethanol and water mixture and ﬁnal
washing with water to remove impurities associated with
industrial scale, manufacturing or absorbed during storage
or handling. For rapid release of drug, weak acid cation ex-
change carboxylic acid resins were tried. Preparation of resin-
ate is normally done by two techniques (1) Bateh and (2)
Column technique, but resinates were prepared using batch
method.
Among three different resins viz. Indion 204, Indion 234
and Indion 414, the Indion 234 gave highest amount of drugloading (89.58%± 0.26) and taste masking, because of its
swelling and hydration properties hence Indion 234 was se-
lected for further studies. Before designing a suitable delivery
system, the main challenge is to optimize the conditions of res-
inate preparation, in order to obtain the desired drug loading
in the resinates. Various processing parameters, viz. drug–resin
ratio, pH, temperature and drug concentration, affected either
rate or extent of loading of doxylamine succinate on Indion
234.
Study on effect of drug–resin ratio suggests higher drug
loading at drug to resin ratio 1:1 and above. The plot of%
drug loaded Vs time demonstrates that% uptake of drug from
solution is highest for the ratio 1:2 i.e., 88.63%± 1.39, for this
reason drug–resin ratio 1:2 was selected as optimized ratio.
Doxylamine succinate–Indion 234, complexation involves the
exchange of ionizable drug and metal ions in resin, which in
turn depends on the pKa of drug and resin. Such a mode of
complexation between amino group of doxylamine succinate
and –COO-K+ functionality of Indion 234 can be affected
by the pH of the reacting media. The complexation was en-
hanced with increasing pH from 3 to 7. A maximum of
80.87%± 0.26 wt/wt drug loading was obtained at pH 5
(i.e., at pKa of doxylamine succinate).
As shown in Fig. 3, as pH increased above 5 the percentage
of drug loading decreased. The pH of the solution affects both
solubility and the degree of ionization of drug and resin. The
results can be attributed to the fact that doxylamine succinate
has a pKa 4.4 and hence will have maximum solubility and
complete ionization in this range. The decreased complexation
at lower pH is due to excess H+ ions in the solution, which
have more binding afﬁnity to the –COO groups of resin and
compete with the drug for binding.
The temperature also affected the complexation. Highest
drug loading on resin occurred (90.71%± 0.70) at tempera-
ture 50 C. Increased temperature during complexation in-
creases ionization of drug and resin. High temperatures may
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Figure 3 Effect of pH on drug loading.
234 T.Y. Puttewar et al.also cause swelling of resin, higher temperatures tend to in-
crease the diffusion rate of ions by decreasing the thickness
of exhaustive exchange zone. Drug concentration per ml of
loading solution was found to affect the loading time and
had no appreciable effect on extent of uptake. Drug loading
was faster at higher drug concentration, probably because of
efﬁcient competition for binding site with other ions in solu-
tion. Thus higher drug concentration can be used to reduce
the processing time and larger batches can be processed in rel-
atively smaller vessels. The extent of drug loading was faster at
drug concentration (4 mg/ml) i.e., 91.47%± 0.46. Complexa-
tion between the drug and resin is essentially a process of dif-
fusion of ions between the resin and surrounding drug
solution.
The results reveal that a 30-min swelling time of Indion 234
in deionized water gave the maximum doxylamine succinate
loading above 80%. The swelling and hydration properties
of Indion 234 affect the rate of Ion exchange, which in turn af-
fect the percentage drug loading. In unswollen resin matrix, the
exchangeable groups are latent and coiled towards the back-
bone, hence less drug loading efﬁciency. The percentage of
drug loading stirring time was studied. This study revealed that
as time increased the KDM values increased rapidly up to
20 min, it is surprising to note the high exchange rate between
20 and 30 min. This ﬁnding may indicate the signiﬁcant
involvement of Vander Waals forces or chemisorption taking
place along with exchange during complexation. Increasing
the stirring time above 30 min did not further increase the
KDM values. Hence 30 min contact time between drug and re-
sin could be optimized to equilibrate the ion exchange processTable 6 Formulation composition.
Sr. No. Table ingredients (mg) Formulation
F1 F
1 DRC 30 3
2 Pyridoxine HCL 10 1
3 Microcrystalline cellulose (Vivapur 102) 244.32 –
4 Lactose (Lactopress Anhydrous 250) – 2
5 Crospovidone (Kollidon CL-SF) 9.12 9
6 Magnesium stearate 2.80 2
7 Aspartame 3.75 3
8 Flavour (Vanilla) q.s q
Tablets are prepared in batch of 30; DRC: drug–resin complex.to achieve maximum drug loading. This study indicated that
optimum ion exchange could be completed in a short period
of 30 min.
Doxylamine succinate release from drug–resin adsorbate
was observed using United States Pharmacopoeia USP 24 type
II dissolution apparatus and drug release was 97.37%± 2.88
within 30 min.
In vitro drug release in average salivary pH of 6.7 was less
than 5% within 60 s. The presence of exchangeable ions of ion-
izable electrolytes in salivary ﬂuid may be responsible for this
release. Resinate is stable in salivary pH for a period of admin-
istration. The amount released is insufﬁcient to impart bitter
taste while the formulation passes through the mouth to fur-
ther parts of gastrointestinal tract.
A drug–resin complex is made from the bitter drug and ion
exchange resins. The nature of the complex is such that the
average pH of 6.7 and cation concentration at about 40 meq/
lit in saliva are not able to break the drug–resin complex but
it is weak enough to be broken down by the hydrochloric acid
present in the stomach, thus the drug–resin complex is abso-
lutely tasteless and stable, with no aftertaste. The complexa-
tion of doxylamine succinate and Indion 234 produces
amorphous tasteless drug resinate. Taste evaluation in volun-
teers found the DRC to be tasteless and agreeable with maxi-
mum acceptability.
The XRPD pattern of pure drug contained a number of
sharp peaks, while the resin showed a diffused peak. The
XRPD patterns of the physical dispersions showed simply
the sum of the characteristic peaks were observed in the XRPD
patterns for the complexes regardless of presence of drug.
According to the data from XRPD, the molecular state of pure
drug was crystalline, but that of the resin was amorphus. The
molecular state of the drug prepared as drug–resin complexes
was changed from the crystalline to the amorphous state.
These results demonstrated that the entrapped molecule of
drug was dispersed monomolecularly in the resin bead. In
the case of physical dispersions of drug and Indion 234, drug
molecules are outside the resin beads. Thus, DRC is amor-
phous in nature and shows faster dissolution due to improved
solubility. FTIR spectra of pure drug, pure resin, physical mix-
ture of drug and resin and resinate conﬁrms the complexation
between drug and resin, and support the ﬁndings of XRPD
studies. The time intensity study adopted for taste evaluation
reviled considerable masking of bitter taste of doxylamine suc-
cinate, which makes Indion 234 suitable for taste masking of
doxylamine succinate.2 F3 F4 F5 F6 F7
0 30 30 30 30 30
0 10 10 10 10 10
122.16 162.88 183.24 81.44 61.08
44.32 122.16 81.44 61.08 162.88 183.24
.12 9.12 9.12 9.12 9.12 9.12
.80 2.80 2.80 2.80 2.80 2.80
.75 3.75 3.75 3.75 3.75 3.75
.s q.s q.s q.s q.s q.s
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Doxylamine succinate orodispersible tablets were prepared
according to the formula given in Table 6. A total number
of seven formulations were prepared. All the ingredients
were passed through 60 mesh sieve separately and collected.
The ingredients were weighed and mixed in a geometrical or-
der. First MCC, Lactose and crospovidone were mixed to-
gether. Drug complex was then added and was mixed for
10–15 min. Finally to this blend aspartame and magnesium
stearate were added and mixed further for 10–15 min (Fu
et al., 1991). The tablets were then compressed using
10 mm size punches to get a tablet of 300 mg weight. The
data for the selection of various superdisintegrants and their
concentration for series S1–S12 are given as Supplementary
data
Before tablet preparation, the mixture blend of all the for-
mulations were subjected to pre-compression parameters like
angle of repose, bulk density, tapped density,% compressibil-
ity and ﬂowability. The orodispersible tablets prepared sub-
jected to post-compression parameters like, content
uniformity, hardness, friability, weight variation, dissolution
and in vitro disintegration. Batches were prepared by direct
compression method.
Direct compression is the preferred method for preparation
of tablets. Current usage of the term ‘‘direct compression’’ is
used to deﬁne the process by which tablets are compressed
from the powder blends of active ingredient/s and suitable
excipients. No pre treatment of the powder blends by wet or
dry granulation is involved.
2.2.5. Evaluation of blend for orodispersible tablets
Blend was evaluated for ﬂow properties.
2.2.5.1. Angle of repose. The ﬂow characteristics are measured
by angle of repose. Improper ﬂow of powder is due to fric-
tional forces between the particles. These frictional forces are
quantiﬁed by angle of repose. Angle of repose is deﬁned as
the maximum angle possible between the surface of a pile of
the powder and the horizontal plane.
By deﬁnition
tan h ¼ h
r
h ¼ tan1 h
r
where h is the height of pile; r is radius of the base of the pile; h
is the angle of repose.
2.2.5.2. Bulk density. It is deﬁned mathematically as
Bulk density ðqÞ ¼ mass of a powder ðwÞ
bulk volume ðVbÞ
When particles are packed loosely, lots of gaps between
particles are observed. Hence bulk volume increases making
the powder light. Based on bulk volume, powders are classiﬁed
as ‘‘light’’ and ‘‘heavy’’. Light powders have high bulk volume.
On the other hand, smaller particles may sift between the lar-
ger particles, the powder assume low bulk volume or high bulk
density. Such powders are called heavy powders. The bulk
density depends on particle size distribution, shape and cohe-
siveness of particles.A powder (about 60 g) is passed through a standard sieve
No. 20. A weighed amount (approximately 50 g) is introduced
into a 100 ml graduated cylinder. The cylinder is ﬁxed on the
Bulk density. Apparatus and the timer knob is set (regulator)
for 100 tappings. The volume occupied the powder is noted.
Further, another 50 taps may be continued and the ﬁnal vol-
ume is noted. For reproducible results, the process of tapings
may be continued until concurrent volume is achieved. This ﬁ-
nal volume is the bulk volume. Then bulk density is calculated
using equation. Bulk volume is also measured by dropping the
cylinder (containing powder) onto a hard wooden surface 3
times from a height of 1 inch at 2 s intervals. Sometimes, to
get an appropriate volume, the container has to be dropped
or tapped 500 times.
2.2.5.3. Tapped density. Tapped density was determined by
USP method II. The powder sample under test was screened
through sieve No. 18 and 10 g of tablet bend was ﬁlled in
100 ml graduated cylinder of tap density tester (Electrolab,
ETD 1020). The mechanical tapping of the cylinder was car-
ried out using tapped density tester at a nominal rate of 250
drops per minute for 500 times initially and the initial tapped
volume (Va) was noted. Tapping was proceeded further for
additional 750 times and volume was noted. The difference
between two tapping volumes was calculated. Tapping was
continued for additional 1250 times if the difference is more
than 2%. This was continued in increments of 1250 taps until
difference between volumes of subsequent tapings was less
than 2%. This volume was noted as, the ﬁnal tapped volume
(Vb).
The tapped density (Dt) was calculated in g/ml by the
formula,
Dt ¼M=Vb
where M is the weight of sample powder taken; Vb is tapped
volume.
Determinations were carried out in 3 replicates. The mean
value of three determinations are considered.
2.2.5.4. Compressibility. Carr’s consolidation index: It is de-
ﬁned as:
Consolidation index ¼ tapped density fluff density
tapped density
 100
This property is also known as compressibility. It is indi-
rectly related to the relative ﬂow rate, cohesiveness and particle
size. It is simple, fast and popular method of predicting powder
ﬂow characteristics.
Fluff (poured) density is the ratio of mass of powder to the
ﬂuff volume. Fluff volume is the volume occupied by a certain
mass, when gently poured into a measuring cylinder.
Tapped density is the ratio of mass of powder to the tapped
volume. Tapped volume is the volume occupied by the same
mass of the powder after a standard tapping of a measure.
Compressibility index can be a measure of the potential
strength that a powder could build up in its arch in a hopper
and also the ease with which such an arch could be broken.
Using a suitable adhesive, the base of a 10 ml tarred mea-
suring cylinder is ﬁxed to the standard rubber bung at the
top of the 250 ml cylinder. A powder sample (about 5.0 g) is
transferred into the tarred 10 ml cylinder with the help of a
funnel. The 250 ml measuring cylinder is placed on the tapping
236 T.Y. Puttewar et al.apparatus. The initial volume occupied by the powder is de-
noted as V0.
The contents are tapped in the following order, 2, 4, 6, 8,
10, 20, 30 and 50 taps. After completing the tapings, the
volume is denoted as V2, V4 . . . V50.
The powder is carefully collected from the cylinder and
weighed (W)
Fluff density ðqb minimumÞ ¼W=V0g=cc
Tapped density ðqb maximumÞ ¼W=V50g=cc2.2.5.5. Powder ﬂowability. Before tablating the ﬂowability of
the mix ingredients of each formulation was studied. Although
the pure doxylamine succinate was non ﬂowable the addition
of excipients resulted in a formation with percent compressibil-
ity between 12–16 and angle of repose between 20–30 indicat-
ing that ﬂowability had signiﬁcantly improved (Table 7).
2.2.6. Evaluation of tablets
The formulated orodispessible tablet were evaluated for differ-
ent parameters like, weight variation (Borodkin and Sandburg,
1971), hardness, friability, wetting time (Kuchekar et al.,
2004), water absorption ratio (Pisal et al., 2004), content uni-
formity and dissolution (Aly et al., 2005).
2.2.6.1. Weight variation. With a tablet designed to contain a
speciﬁc amount of drug in a speciﬁc amount of tablet formula,
the weight of the tablet being made is routinely measured to
help ensure that a tablet contains the proper amount of drug.
In practice, composite samples of tablets (usually 10) are taken
and weighed throughout the compression process. The com-
posite weight divided by 10, however, provides an average
weight but contains the usual problems of averaged values.
Within the composite sample that has an acceptable average
weight, there could be tablets excessively overweight or under-
weight. To help alleviate this problem the United States Phar-
macopoeia (USP)/National Formulary (NF) provides limits
for the permissible variations in the weights of individual tab-
lets expressed as a percentage of the average weight of the sam-
ple. The USP weight variation test is run by weighing 20
tablets individually, calculating the average weight, and com-
paring the individual tablet weights to the average. The tablets
meet the USP test if no more than 2 tablets are out side the
percentage limit and if no tablet differs by more than 2 times
the percentage limit. The weight variation tolerances for un-
coated tablets differ depending on average tablet weight.
2.2.6.2. Hardness. The hardness of a tablet is indicative of its
tensile strength and is measured in terms of load/pressureTable 7 Evaluation of mixed blend of drug and excipients.
Sr. No. Property Formulations
F1 F2 F3
1 Angle of repose 25.56 ± 0.70 25.13 ± 0.78 26.25
2 Bulk density gm/cm3 0.56 ± 0.011 0.56 ± 0.018 0.57 ±
3 Tapped density gm/cm3 0.65 ± 0.008 0.66 ± 0.024 0.67 ±
4 % compressibility 13.86 ± 1.42 13.7 ± 1.13 14.49
5 Flowability Good Good Good
Results are mean of three determinations.required to crush it when placed on its edge. A number of han-
dy hardness testers such as Mosanto type or Pﬁzer type are
currently in use. Hardness of about 5 kg is considered to be
minimum for uncoated tablets for mechanical stability. The
hardness is a function of physical properties of granules like
their hardness and deformation under load, binders and above
all the compressional force. The hardness has inﬂuence on dis-
integration and dissolution times and is as such a factor that
may affect bioavailabilities.
2.2.6.3. Friability. Generally it refers to loss in weight of tablets
in the containers due to removal of ﬁne particles from their
surfaces. However, in wider sense chipping and fragmentations
can also be included in friability. Friability generally reﬂects
poor cohesion of tablet ingredients. Standard devices have
been fabricated to measure friability. Generally such instru-
ments, marketed as ‘Friability Test Apparatus’ or ‘Friabilators’,
consist of a circular plastic chamber, divided into 2–3 compart-
ments. The chamber rotates at a speed of 25 r.p.m. and drops
the tablets by a distance of 15 cm. Preweighed tablets are
placed in the apparatus, which is given 100 revolutions after
which the tablets are weighed once again. The difference in
the two weights represents friability. The weight loss should
not be more than one per cent.
2.2.6.4. Wetting time and water absorption ratio. The proce-
dures similar to those used Bi et al., where used to measure
tablet wetting time and water absorption ratio. A piece of tis-
sue paper folded twice was placed in a small petridish contain-
ing 6 ml of water. A tablet was kept on the paper and time
required for complete wetting was measured. The wetted tablet
was then weighed.
Water absorption ratio, R, was determined using the fol-
lowing equations:
R ¼ fðWa WbÞ Wbg  100
where, Wb =weight of tablet before water absorption, and
Wa =weight of tablets after absorption.
2.2.6.5. Disintegration time. In vitro disintegration time of ta-
bles from each formulation were determined by using digital
tablet disintegration apparatus. In vitro disintegration test
was carried out at 37 ± 2 C in 900 ml distilled water.
2.2.6.6. Content uniformity. Transfer 1 ﬁnely powdered tablet
to a 100 ml volumetric ﬂack containing 65 ml of 0.1 N hydro-
chloric acid, Shake frequently during a 10 min period, dilute
with 0.1 N hydrochloric acid to volume, and mix. Allow the
insoluble material to settle, and ﬁlter, discarding the ﬁrst
20 ml of the ﬁltrate. Dilute a Portion of the subsequent ﬁltrateF4 F5 F6 F7
± 0.81 26.88 ± 1.77 26.61 ± 0.44 26.70 ± 1.63 26.45 ± 1.15
0.008 0.57 ± 0.024 0.57 ± 0.016 0.57 ± 0.004 0.55 ± 0.020
0.014 0.67 ± 0.008 0.67 ± 0.016 0.66 ± 0.012 0.65 ± 0.014
± 0.63 13.96 ± 2.08 13.93 ± 0.77 13.54 ± 0.98 14.88 ± 1.98
Good Good Good Good
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Figure 4 Dissolution study of different batches.
Table 10 Comparison of optimized formulation with con-
ventional marketed tablet.
Sr.
No.
Time
(min)
Cumulative % release
from conventional
marketed tablet
Cumulative % release
from optimized batch
1 00 00 00
2 2 14.81 ± 10.00 42.59 ± 3.78
3 4 25.61 ± 6.64 69.59 ± 6.63
4 6 31.01 ± 5.00 90.42 ± 4.75
5 8 39.5 ± 8.93 95.82 ± 1.89
6 10 49.53 ± 7.56 99.68 ± 1.09
7 12 56.48 ± 3.78 99.68 ± 2.88
8 15 56.47 ± 1.89 100.45 ± 1.89
Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate 237quantitatively and stepwise, if necessary, with 0.1 N hydro-
chloric acid to provide a solution containing approximately
25 lg of doxylamine succinate per ml. Concomitantly deter-
mine the absorbances of this solution and of a standard solu-
tion of USP doxylamine Succinate RS in the same medium
having a known concentration of about 25 lg per ml in 1-cm
cells at the wavelength of maximum absorbance at about
262 nm, with a suitable spectrophotometer, using 0.1 N hydro-
chloric acid as the blank. Calculate the quantity in mg, of
C17H22N2OÆC4H6O4 in the tablet taken by the formula:
ðTC=DÞðAU=ASÞ
in which; T is the labeled quantity in mg, of doxylamine succi-
nate in the tablet, C is the concentration, in lg per ml of USP
doxylamine succinate RS in the standard solution, D is concen-
tration, in lg per ml doxylamine succinate in the solution from
the tablet, based on the labeled quantity per tablet and the ex-
tent of dilution and AU and AS are the absorbances of the
solution from the tablet and the standard solution, respec-
tively, results are reported in Table 8.
2.2.6.7. Dissolution studies. The in vitro dissolution studies were
carried out using USP apparatus type II at 50 rpm. The disso-
lution medium used was 0.01 N hydrocloric acid (900 ml)
maintained at 37 ± 0.5 C. Aliquots of dissolution media were
withdrawn at different intervals and content of doxylamine
succinate was measured by determining absorbance at
262 nm (Table 9). The dissolution experiments were conducted
in triplicate. Not less than 80% (Q) of the labeled amount of
C17H22N2OÆC4H6O4 is dissolved in 30 min. The comparative
results are shown as Fig. 4.Table 8 Evaluation of orodispersible tablet.
Sr. No. Parameters Formulation
F1 F2 F3 F4 F5 F6 F7
1 Weight variation Passes Passes Passes Passes Passes Passes Passes
2 Hardness kg/sq cm 4.13 ± 0.24 4.23 ± 0.30 4.03 ± 0.26 4.16 ± 0.20 4.06 ± 0.28 4.0 ± 0.29 4.46 ± 0.12
3 Friability % 0.79 ± 0.012 0.76 ± 0.045 0.74 ± 0.036 0.77 ± 0.021 0.76 ± 0.044 0.72 ± 0.024 0.73 ± 0.059
4 Disintegration time (s) 32.52 ± 0.44 57.50 ± 1.04 46.55 ± 1.32 30.37 ± 0.66 25.24 ± 0.75 49.94 ± 1.34 57.09 ± 0.76
5 Content uniformity 97.92 ± 0.32 97.95 ± 0.07 98.28 ± 0.31 98.03 ± 0.05 98.89 ± 0.13 98.14 ± 0.22 98.32 ± 0.26
6 Wetting time (s) 10.04 ± 1.44 10.91 ± 0.90 11.95 ± 1.31 11.09 ± 0.61 10.60 ± 1.23 11.68 ± 0.40 13.34 ± 1.01
7 % Water absorption ratio 91.64 ± 0.32 95.64 ± 0.19 99.8 ± 0.13 103.75 ± 0.20 101.50 ± 0.32 72.8 ± 0.35 115.43 ± 0.60
Results are mean of three determinations.
Table 9 Dissolution study of different batches.
Time (min) Cumulative % drug release
F1 F2 F3 F4 F5 F6 F7
0 00 00 00 00 00 00 00
2 21.75 ± 11.33 29.47 ± 6.64 37.95 ± 13.23 41.81 ± 6.63 41.81 ± 4.75 40.27 ± 3.78 41.04 ± 11.39
4 52.62 ± 3.93 46.44 ± 12.30 51.84 ± 13.23 58.79 ± 5.67 67.27 ± 10.40 63.42 ± 7.56 57.25 ± 3.93
6 72.68 ± 9.44 68.05 ± 3.78 70.36 ± 11.33 74.99 ± 7.55 91.19 ± 5.67 81.16 ± 5.77 79.62 ± 3.77
8 83.48 ± 2.88 93.51 ± 1.89 95.05 ± 8.52 85.02 ± 2.88 98.14 ± 3.78 98.14 ± 1.89 93.51 ± 7.56
10 95.83 ± 3.78 93.51 ± 7.56 93.51 ± 3.78 98.14 ± 1.89 100.45 ± 1.89 98.91 ± 2.88 95.05 ± 2.88
12 95.82 ± 1.89 91.19 ± 5.67 93.51 ± 7.56 98.14 ± 3.78 101.23 ± 3.93 98.91 ± 1.09 95.82 ± 1.89
15 95.83 ± 7.56 93.51 ± 9.45 93.51 ± 5.67 98.91 ± 1.09 100.46 ± 3.78 99.68 ± 2.18 95.82 ± 5.67
Results are mean of three determinations.
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Figure 5 Comparison of optimised formulation with conventional marketed tablet.
Table 14 Dissolution proﬁle for 75 C.
Sr. No. Time (min) Cumulative % drug release
1 month 2 month 3 month
1 0 0 0 0
2 2 26.38 ± 1.89 37.95 ± 1.89 27.92 ± 12.15
3 4 43.36 ± 3.93 56.48 ± 3.78 58.79 ± 3.78
4 6 58.02 ± 6.64 76.54 ± 5.77 79.62 ± 3.77
5 8 81.16 ± 2.88 83.48 ± 1.08 98.91 ± 2.88
6 10 97.37 ± 2.88 98.14 ± 1.89 100.45 ± 3.27
238 T.Y. Puttewar et al.2.2.6.8. Comparison of optimized formulation with conventional
marketed tablet. In vitro dissolution studies for batch F5 and
conventional tablet were carried out using USP apparatus type
II at 50 rpm, which shows that the drug release was more than
80% within 15 min which is better than conventional marketed
tablet. The results are shown in Table 10, a plot of comparison
is shown in Fig. 5.
2.2.6.9. Stability study. Stability study was conducted by stor-
ing tablets at 40 C± 2 C/75 C± 5% relative humidity forTable 11 Stability data for 40 C.
Sr.
No.
Evaluation 1 month 2 month 3 month
1 Hardness 3.96 ± 0.16 4.0 ± 0.21 4.1 ± 0.08
2 Disintegration
time
24.73 ± 0.43 26.35 ± 0.77 28.36 ± 0.53
3 Content
uniformity
98.17 ± 0.14 97.98 ± 0.08 99.96 ± 2.19
Table 12 Dissolution proﬁle for 40 C.
Sr. No. Time (min) Cumulative % drug release
1 month 2 month 3 month
1 0 0 0 0
2 2 18.66 ± 6.07 25.61 ± 3.93 23.29 ± 5.77
3 4 30.24 ± 9.70 40.27 ± 13.23 38.79 ± 6.64
4 6 57.25 ± 3.93 70.36 ± 5.67 54.93 ± 2.88
5 8 76.53 ± 2.88 87.34 ± 4.75 77.31 ± 5.66
6 10 94.28 ± 7.15 98.14 ± 3.78 92.74 ± 3.93
7 12 99.68 ± 2.88 101.22 ± 2.18 99.68 ± 1.09
8 15 99.68 ± 1.09 100.45 ± 1.89 99.68 ± 2.18
Table 13 Stability data for 75 C.
Sr.
No.
Evaluation 1 month 2 month 3 month
1 Hardness 4.13 ± 0.12 4.06 ± 0.09 3.86 ± 0.04
2 Disintegration
time
29.41 ± 1.16 27.75 ± 2.38 29.27 ± 2.73
3 Content
uniformity
99.26 ± 2.19 99.07 ± 0.72 99.23 ± 0.98
7 12 98.14 ± 3.78 100.45 ± 1.89 100.46 ± 3.78
8 15 98.14 ± 5.67 100.46 ± 3.78 101.22 ± 2.18
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Figure 6 Dissolution proﬁle for 40 C.three months (Gohel and Jogani, 2005). The content and dis-
solution behaviours from orodispersible tablets were tested
monthly for three months (Tables 11–14).
Each tablets was individually weighed and wrapped in a
aluminium foil and packed in black PVC bottle and put at
above speciﬁed conditions in a heating humidity chamber for
three months. After each month tablet sample was analysed
for hardness, disintegration, time, dissolution and drug con-
tent. The results are shown below, comparative account is gi-
ven in the form of plots (Figs. 6 and 7).
3. Result and discussion
The formulation of orodispersible tablet was made by using
doxylamine succinate–resin complex (resinate C). Batches S1–
S7 were prepared by direct compression to select the disinte-
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Figure 7 Dissolution proﬁle for 75 C.
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containing crospovidone (batch S6 and S7) exhibit quick disin-
tegration time and followed by tablets containing croscarm-
elleose sodium and sodium starch glycolate. The probable
reason for delayed the disintegration time of the tablet might
be slow water uptake or more gelling tendency of croscarmel-
lose sodium and sodium starch glycolate than crospovidone.
Hence, crospovidone was selected as a disintegrant for the fur-
ther studies. From the results it was obvious that the optimum
concentration of crospovidone might be less than 10%.
Batches S8–S12 were prepared to optimize the optimum con-
centration of crospovidone in order to obtain rapid disintegra-
tion at minimum concentration. Batches S6 (28.78 ± 0.48), S7
(39.30 ± 0.84) and S8 (26.55 ± 0.39) exhibited decrease in dis-
integration time and wetting time (10–12 s). But S8 had shown
more decrease in disintegration time and wetting for this rea-
son batch S8 was selected. In batch S7 disintegration time
(39.30 ± 0.84) was found more than batch S8, such a behavior
of superdisintegrants may be due to the blockade of capillary
pores which prevents the entry of ﬂuid into the tablet. For for-
mulation of orodispersible tablet the blend was prepared and
subjected to evaluation. The composition of blend of each
batch is given in Table 6. Pyridoxine hydrochloride is added
in the formulation because it helps in the healthy functioning
of the nervous system and brain. Pyridoxine hydrochloride is
involved in the production of hemoglobin in red blood cells
and neurotransmitters like serotonin. It also improves energy
production in the body and it is also essential for the normal
reproductive process and healthy pregnancies.
The tablet blend of all the batches were evaluated for dif-
ferent derived properties viz.-angle of repose (between 25 and
27), Bulk density (between 0.55 and 0.57 gm/cm3), Tapped
Density (0.65–0.67 gm/cm3), Compressibility index (between
13 and 15, and ﬂowability (good). The results of Angle of re-
pose and compressibility indicated that the ﬂowability of
blend is signiﬁcantly good. Orodispersible tablets were pre-
pared in batches F1–F7 and evaluated for tablet properties
like, weight variation, hardness, friability, wetting time, water
absorption ratio, content uniformity, disintegration time and
dissolution.
All the tablets passed weight variation test as the percent
weight variation was within the pharmacopoeial limits. Hard-
ness were shown in the range of 4.0 ± 0.29–4.46 ± 0.12 kg/
cm2 in all the formulations which indicated good mechanical
strength with an ability to withstand physical and mechanical
stress conditions while handling. In all the formulations, thefriability value was less than 1% and meets the ofﬁcial limit.
The results of disintegration of all the tablets were found to
be within prescribed limits and satisﬁed the criteria of Orodis-
persible tablet. The values were found to be in the range of
25.24 ± 0.75–57.50 ± 1.04. The percentage drug content of
all the tablets was found to be between 97.92 ± 0.32 and
98.89 ± 0.13 of doxylamine succinate which was within
acceptable limit. All the tablets prepared were subjected for re-
lease proﬁle. The tablets prepared from crospovidone i.e., F1–
F7 showed a drug release between 83.48 ± 2.88 and
101.23 ± 3.93. The wetting time and water absorption ratio
was also in acceptable limit i.e., between 10.04 ± 1.44–
13.34 ± 1.01 and 72.8 ± 0.35–115.43 ± 0.63. Among seven
Batches, Batch F5 is selected as optimized batch because of
its lowest disintegration time and highest drug release. In com-
parison, formulation F5 was compared with conventional mar-
keted formulation. The drug release of marketed product and
F5 formulation was found to be 56.47 ± 1.89 and
100.45 ± 1.89 at the end of 15 min. Stability was performed
on formulation F5. Results for hardness, disintegration time,
dissolution and content uniformity show no appreciable
change up to 3 months of accelerated stability studies.4. Conclusion
During the last decade, orodispersible tablets that make tablets
disintegrate in the mouth without chewing and additional
water intake has drawn a great deal of attention. Because of
the increase in the average life span and the decline, with
age, in swallowing ability, oral tablets administration to pa-
tients is a signiﬁcant problem and has become the object of
public attention. Solid dosage forms that can be dissolved or
suspended with water in the mouth for easy swallowing are
highly desirable for the pediatric and geriatric population, as
well as other patients who prefer the convenience of readily
administered dosage form. Organoleptic characteristics of
pharmaceutical products, i.e., mainly appearance, odour and
taste are essential factors in assessing the consumer acceptabil-
ity, thereby the commercial success in the market. Thus taste
masking of oral pharmaceuticals has become a potential tool
to improve patient compliance and commercial success of the
product. Ion exchange resins are solid and suitably insoluble
high molecular weight polyelectrolytes that can exchange their
mobile ions of equal charge with the surrounding medium. The
resulting ion-exchange is reversible and stoichiometric with the
displacement of one ionic species by another.
Molecular properties of resinate were studied using XRPD
and FTIR, both suggested complexation between drug and re-
sin. The change in crystalline form of drug to amorphous form
due to monomolecular dispersion was suggested by these stud-
ies. The complexes were successfully formulated into orodis-
persible tablets. Three superdisintegrants were screened in
order to determine most suitable superdisintegrant, among
these, 9% w/w crospovidone was selected and tried for further
studies. A total number of seven formulations were prepared
by direct compression technique.
In the end of it can be concluded that pharmaceuticals com-
plexed using ion exchange resins have shown improved orga-
noleptic performance of pharmaceuticals and better patient
compliance. This study shows an urgent need for a new dosage
form which can improve patient compliance. For better taste
240 T.Y. Puttewar et al.masking effective techniques are being developed constantly in
the pharmaceutical industry. Presently the use of these tech-
niques depends on the nature of the drug, thus the use of cat-
ion exchange resin offers good taste masking of doxylamine
succinate and its formulation into orodispersible table offers
advantages over conventional tablet.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.jksus.2010.05.003.
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